RFA
VIRX

Reilly Financial Advisors’s Viracta Therapeutics, Inc. Common Stock VIRX Stock Holding History

Reilly Financial Advisors’s Portfolio VIRX Stock Details VIRX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2017
Q1 		– Sell
-2
Closed – – 964
2016
Q4 		$0 Hold
2
– – ﹤0.01% 914
2016
Q3 		$0 Hold
2
– – ﹤0.01% 900
2016
Q2 		$0 Hold
2
– – ﹤0.01% 993
2016
Q1 		$0 Hold
2
– – ﹤0.01% 1291
2015
Q4 		$0 Hold
2
– – ﹤0.01% 1408
2015
Q3 		$0 Hold
2
– – ﹤0.01% 1404
2015
Q2 		$2K Buy
+2
New +$1.06K ﹤0.01% 1237

Other funds holding VIRX

BI
BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return
GPP
Great Point Partners Greenwich, Connecticut $435M AUM 318.81% 1-Year Est. Return
NMC
NEA Management Company Timonium, Maryland $1.76B AUM 223.33% 1-Year Est. Return
PAI
Palo Alto Investors Palo Alto, California $654M AUM 77.8% 1-Year Est. Return
DCM
DAFNA Capital Management Los Angeles, California $440M AUM 109.12% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
OM
Opaleye Management Boston, Massachusetts $759M AUM 124.8% 1-Year Est. Return
BC
Boxer Capital San Diego, California $2.04B AUM 108.39% 1-Year Est. Return
CAM
Cormorant Asset Management Boston, Massachusetts $1.99B AUM 737.95% 1-Year Est. Return

Reilly Financial Advisors's VIRX Position: Q1 2017 in Review

Reilly Financial Advisors sold out of Viracta Therapeutics, Inc. Common Stock (VIRX) in Q1 2017, closing a stake of 2 shares.

Reilly Financial Advisors first reported a position in VIRX in Q2 2015 and held it in 7 quarters. The position peaked at $2K in Q2 2015. 41 funds tracked by Wall St. Rank hold VIRX as of Q1 2017.

  • Reilly Financial Advisors reported no remaining Viracta Therapeutics, Inc. Common Stock position as of Q1 2017 after selling out during the quarter.
  • Reilly Financial Advisors sold 2 Viracta Therapeutics, Inc. Common Stock shares in Q1 2017.
  • Reilly Financial Advisors first reported a position in Viracta Therapeutics, Inc. Common Stock in Q2 2015 and held it in 7 quarters.
  • Reilly Financial Advisors's Viracta Therapeutics, Inc. Common Stock position peaked at $2K in Q2 2015.
  • 41 funds tracked by Wall St. Rank held Viracta Therapeutics, Inc. Common Stock as of Q1 2017.

Based on Reilly Financial Advisors's 13F filing for Q1 2017, filed 18 Apr 2017.